Browse our anti-Activity-Dependent Neuroprotector Homeobox (ADNP) Antibodies

Mouse (Murine) Activity-Dependent Neuroprotector Homeobox (ADNP) interaction partners

1. results reveal that ADNP, via the recruitment of HP1 (show CBX5 Antibodies) and CHD4 (show CHD4 Antibodies), regulates the expression of genes that are crucial for maintaining distinct cellular states and assures accurate cell fate decisions upon external cues

2. Hippocampal ADNP expression was greater in males than in females. Haploinsufficiency led to increased hippocampal eIF4E and ApoE expression.

3. the newly identified shared microtubule target of NAP (show CTNNBL1 Antibodies)/ADNP is directly implicated in synaptic plasticity, explaining the breadth and efficiency of neuroprotective/neurotrophic capacities

4. ADNP expression is increased in the cerebral cortex of a transgenic mouse model of Alzheimer disease.

5. NAP (show CTNNBL1 Antibodies) is an ADNP derived peptide that modulates the tubulin (show TUBB Antibodies) pool in mice and rats

6. Results support the hypothesis that ADNP expression is related to early or mild Alzheimer's disease progression by a VIP (show Vip Antibodies)-independent mechanism.

7. ADNP is identified as a new key gene essential for organogenesis in the developing embryo and may be implicated as a clinical target associated with proper neurodevelopment.

8. ADNP has a part in the estrus cycle as an affecter or an effector.

9. The mRNA transcripts for activity-dependent neuroprotective protein (ADNP, the NAP (show CTNNBL1 Antibodies) containing protein) were shown to increase 29 days post closed head injury in the injured hemisphere of Mac-1 (show ITGAM Antibodies) expressing mice.

10. ADNP expression is mediated through multiple receptors and signaling pathways that are regulated by different concentrations of PACAP (show ADCYAP1 Antibodies)

Human Activity-Dependent Neuroprotector Homeobox (ADNP) interaction partners

1. in patients with intellectual disability, autism spectrum disorder and features suggestive of Noonan syndrome should have DNA analysis for the ADNP gene if the Noonan syndrome panel failed to identify a specific mutation.

2. The role of ADNP in autophagy, and in autism, schizophrenia and Alzheimer's disease is described.

3. Our findings indicate that ADNP is a tumor suppressor and promising prognostic marker, and that ketamine treatment with ADNP induction is a potential therapeutic approach that may add benefit to current treatment protocols for patients with colorectal cancer

4. From a clinical standpoint, a differential diagnosis of patients with blepharophimosis should include ADNP mutations in addition to blepharophimosis ptosis epicanthus inversus syndrome, especially when intellectual disability is present

5. The parents of 44/54 ADNP-mutated children reported an almost full erupted (show TSG101 Antibodies) dentition by 1 year of age, including molars and only 10 of the children had teeth within the normal developmental time range.

6. SHANK3 (show SHANK3 Antibodies), CHD8 (show CHD8 Antibodies), and ADNP had distinctly higher scores than all other genes in the dataset describing the genes associated with autism spectrum disorders.

7. The study identified intratumoral heterogeneity (ITH) of the ADNP mutations in colorectal cancers, suggesting that ADNP mutations occurred during tumor progression rather than as an early event. The generation of ITH may influence on clinical outcome of the cancer patients.

8. These findings demonstrate that the down-regulation of protein ADNP is an early pathological alteration and may contribute to dopaminergic neurodegeneration in Parkinson's disease

9. This review covers the myriad of important ADNP-protein interactions and glimpse at their potential meaning in autism, schizophrenia and Alzheimer's disease. [review]

10. ADNP expression was increased in male hippocampus samples compared to female samples.